SARS-CoV-2 re-infection risk in Austria.
COVID-19
PCR
Risk
SARS-CoV-2
epidemiology
re-infection
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
02
02
2021
revised:
10
02
2021
accepted:
11
02
2021
pubmed:
15
2
2021
medline:
19
3
2021
entrez:
14
2
2021
Statut:
ppublish
Résumé
A key question concerning coronavirus disease 2019 (COVID-19) is how effective and long lasting immunity against this disease is in individuals who were previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to evaluate the risk of SARS-CoV-2 re-infections in the general population in Austria. This is a retrospective observational study using national SARS-CoV-2 infection data from the Austrian epidemiological reporting system. As the primary outcome, we aim to compare the odds of SARS-CoV-2 re-infections of COVID-19 survivors of the first wave (February to April 30, 2020) versus the odds of first infections in the remainder general population by tracking polymerase chain reaction (PCR)-confirmed infections of both groups during the second wave from September 1 to November 30, 2020. Re-infection counts are tentative, since it cannot be excluded that the positive PCR in the first and/or second wave might have been a false positive. We recorded 40 tentative re-infections in 14 840 COVID-19 survivors of the first wave (0.27%) and 253 581 infections in 8 885 640 individuals of the remaining general population (2.85%) translating into an odds ratio (95% confidence interval) of 0.09 (0.07 to 0.13). We observed a relatively low re-infection rate of SARS-CoV-2 in Austria. Protection against SARS-CoV-2 after natural infection is comparable with the highest available estimates on vaccine efficacies. Further well-designed research on this issue is urgently needed for improving evidence-based decisions on public health measures and vaccination strategies.
Sections du résumé
BACKGROUND
BACKGROUND
A key question concerning coronavirus disease 2019 (COVID-19) is how effective and long lasting immunity against this disease is in individuals who were previously infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We aimed to evaluate the risk of SARS-CoV-2 re-infections in the general population in Austria.
METHODS
METHODS
This is a retrospective observational study using national SARS-CoV-2 infection data from the Austrian epidemiological reporting system. As the primary outcome, we aim to compare the odds of SARS-CoV-2 re-infections of COVID-19 survivors of the first wave (February to April 30, 2020) versus the odds of first infections in the remainder general population by tracking polymerase chain reaction (PCR)-confirmed infections of both groups during the second wave from September 1 to November 30, 2020. Re-infection counts are tentative, since it cannot be excluded that the positive PCR in the first and/or second wave might have been a false positive.
RESULTS
RESULTS
We recorded 40 tentative re-infections in 14 840 COVID-19 survivors of the first wave (0.27%) and 253 581 infections in 8 885 640 individuals of the remaining general population (2.85%) translating into an odds ratio (95% confidence interval) of 0.09 (0.07 to 0.13).
CONCLUSIONS
CONCLUSIONS
We observed a relatively low re-infection rate of SARS-CoV-2 in Austria. Protection against SARS-CoV-2 after natural infection is comparable with the highest available estimates on vaccine efficacies. Further well-designed research on this issue is urgently needed for improving evidence-based decisions on public health measures and vaccination strategies.
Identifiants
pubmed: 33583018
doi: 10.1111/eci.13520
pmc: PMC7988582
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13520Informations de copyright
© 2021 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Bull World Health Organ. 2021 Jan 1;99(1):19-33F
pubmed: 33716331
Wien Klin Wochenschr. 2020 Nov;132(21-22):645-652
pubmed: 32816114
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Emerg Microbes Infect. 2020 Dec;9(1):2571-2577
pubmed: 33196399
Clin Microbiol Infect. 2021 Mar;27(3):341-351
pubmed: 33188933
Lancet. 2021 Feb 6;397(10273):452-455
pubmed: 33515491
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Clin Infect Dis. 2020 Dec 18;:
pubmed: 33338197
Eur J Clin Invest. 2020 Dec;50(12):e13423
pubmed: 33026101
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
Indian J Med Res. 2020 Jul & Aug;152(1 & 2):48-60
pubmed: 32952144
Lancet. 2020 Oct 10;396(10257):1102-1124
pubmed: 32941825
Cell. 2020 Oct 1;183(1):158-168.e14
pubmed: 32979941
J Infect. 2020 Dec 26;:
pubmed: 33373652
Cell Mol Immunol. 2021 Feb;18(2):318-327
pubmed: 33408342
Eur J Clin Microbiol Infect Dis. 2021 Jan;40(1):13-25
pubmed: 33113040
Emerg Microbes Infect. 2021 Dec;10(1):152-160
pubmed: 33407005
Lancet. 2020 Nov 21;396(10263):1614-1616
pubmed: 33159850
Eur J Clin Invest. 2021 Apr;51(4):e13520
pubmed: 33583018
Lancet Glob Health. 2021 Mar;9(3):e257-e266
pubmed: 33515512
Clin Infect Dis. 2021 Jan 06;:
pubmed: 33400782
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
JAMA. 2020 Dec 15;324(23):2354-2355
pubmed: 33320222
J Infect. 2021 Jan 13;:
pubmed: 33450303
Clin Infect Dis. 2021 Jan 02;:
pubmed: 33386403
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246